Independent Results Support the Use of BioCurex Technology for Gastric Cancer
BioCurex Inc. announced that a group of scientists led by Dr. So Tsuboi from the Shigei Medical Research Hospital, Japan, have published results on the Expression of the receptor for AFP (RECAF) in normal, benign and malignant stomach tissue. The tissue study used a variation of the company's Histo-RECAF kit. The results indicate that RECAF was expressed in 34 out of 47 cancers and not expressed in 59 out of 61 normal or benign tissues. The authors conclude that RECAF may become a new clinically useful marker of gastric cancer. The paper was published in Tumor biology.
The other institutions involved in this study were the Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, the Okayama Citizen's Hospital, and the Oota Memorial Hospital, Fukuyama.
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.